236 related articles for article (PubMed ID: 12741437)
21. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
22. Niacin extended-release/lovastatin: combination therapy for lipid disorders.
Moon YS; Kashyap ML
Expert Opin Pharmacother; 2002 Dec; 3(12):1763-71. PubMed ID: 12472373
[TBL] [Abstract][Full Text] [Related]
23. Optimizing LDL-C lowering with statins.
McKenney JM
Am J Ther; 2004; 11(1):54-9. PubMed ID: 14704596
[TBL] [Abstract][Full Text] [Related]
24. Advances in the understanding and management of dyslipidemia: using niacin-based therapies.
Ito MK
Am J Health Syst Pharm; 2003 Jul; 60(13 Suppl 2):S15-21; quiz S25. PubMed ID: 12901026
[TBL] [Abstract][Full Text] [Related]
25. The therapeutic role of niacin in dyslipidemia management.
Boden WE; Sidhu MS; Toth PP
J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
[TBL] [Abstract][Full Text] [Related]
26. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
27. Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options.
Jones PH
Am Heart J; 2004 Jul; 148(1 Suppl):S9-13. PubMed ID: 15211327
[TBL] [Abstract][Full Text] [Related]
28. Use of combination therapy for dyslipidemia: a lipid clinic approach.
Brown AS
Am J Cardiol; 2002 Nov; 90(10B):44K-49K. PubMed ID: 12467939
[TBL] [Abstract][Full Text] [Related]
29. Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol.
Toth PP; Zarotsky V; Sullivan JM; Laitinen D
Curr Med Res Opin; 2009 Jun; 25(6):1355-63. PubMed ID: 19425901
[TBL] [Abstract][Full Text] [Related]
30. Pharmacotherapy for dyslipidaemia--current therapies and future agents.
Bays H; Stein EA
Expert Opin Pharmacother; 2003 Nov; 4(11):1901-38. PubMed ID: 14596646
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
[TBL] [Abstract][Full Text] [Related]
32. [Niacin--an additive therapeutic approach for optimizing lipid profile].
Wieneke H; Schmermund A; Erbel R
Med Klin (Munich); 2005 Apr; 100(4):186-92. PubMed ID: 15834527
[TBL] [Abstract][Full Text] [Related]
33. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
Jacobson TA
Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
[TBL] [Abstract][Full Text] [Related]
34. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
[TBL] [Abstract][Full Text] [Related]
35. Overview of pharmacologic therapy for the treatment of dyslipidemia.
Lipsy RJ
J Manag Care Pharm; 2003; 9(1 Suppl):9-12. PubMed ID: 14613353
[TBL] [Abstract][Full Text] [Related]
36. Perspectives on low-density lipoprotein cholesterol goal achievement.
Catapano AL
Curr Med Res Opin; 2009 Feb; 25(2):431-47. PubMed ID: 19192988
[TBL] [Abstract][Full Text] [Related]
37. Treatment of hyperlipidemia with combined niacin-statin regimens.
Guyton JR; Capuzzi DM
Am J Cardiol; 1998 Dec; 82(12A):82U-84U; discussion 85-86U. PubMed ID: 9915667
[TBL] [Abstract][Full Text] [Related]
38. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
Ahmed MH
J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
[TBL] [Abstract][Full Text] [Related]
39. Combination niacin and statin therapy in primary and secondary prevention of cardiovascular disease.
Levy DR; Pearson TA
Clin Cardiol; 2005 Jul; 28(7):317-20. PubMed ID: 16075823
[TBL] [Abstract][Full Text] [Related]
40. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
